IBRI science frontiers logo

IBRI Science Frontiers
3rd Annual Seminar Series

Learn More

Diabetic Kidney Disease Remains a Scourge Despite SGLT2 Inhibitor Benefit

Diabetic Kidney Disease Remains a Scourge Despite SGLT2 Inhibitor Benefit

Wednesday, July 06, 2022
9:00 AM - 10:00 AM

Presenter: Matt Breyer, MD

Organization: Janssen Pharmaceutical Company, Boston, Massachusetts

Dr. Matthew Breyer received his MD from Harvard in 1979. Following residency and nephrology training he served as professor of medicine in the division of nephrology at Vanderbilt University Medical School from 1985 to 2007, where his work focused on causes of diabetic and hypertensive kidney disease using transgenic mouse models.

Dr. Breyer received numerous NIH and VA grant awards and from 2001 to 2006 headed the nephropathy sub-group of the NIH Animal Models of Diabetic Complications Consortium (AMDCC).

As a result of his interest in developing treatments for diabetic nephropathy he moved to Eli Lilly and Company in 2007 to oversee a program to develop bio-therapeutics for diabetic kidney disease. In 2009, he was appointed to the position of Chief Scientific Officer Lead Generation Biotechnology Discovery Research at Eli Lilly and Company where he oversaw preclinical target identification and validation of biologics for chronic kidney, metabolic, neurologic and oncologic diseases, and served until 2018.

In 2018, Dr. Breyer joined Janssen Cardiovascular and Metabolism group in Boston as a distinguished scientist, where he guides discovery and development of new drugs for kidney disease.

Register now